Abatacept has beneficial effects in rheumatoid arthritis patients with an inadequate response to anti-TNFα therapy

Clinical and Experimental Rheumatology

Volumn 23, Issue 6, 2005, Pages 767-768

  Emery, Paul ^a,b  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^b CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTINUCLEAR ANTIBODY; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; DNA ANTIBODY; DOUBLE STRANDED DNA; ETANERCEPT; INFLIXIMAB; PLACEBO; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; IMMUNOGENICITY; INFECTION; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCORING SYSTEM; SHORT FORM 36; SHORT SURVEY; SIDE EFFECT; TREATMENT OUTCOME;

EID: 29944441319     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (8)

1. MORELAND LW, ALTEN R, VAN DEN BOSCH F et al.: Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002; 46: 1470-9.
2. EMERY P: The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis. Expert Opin Investig Drugs 2003; 12: 673-81.
3. COLLINS AV, BRODIE DW, GILBERT RJ et al.: The interaction properties of costimulatory molecules revisited. Immunity 2002; 17: 201-
4. KREMER JM, WESTHOVENS R, LEON M et al.: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907-15.
5. KREMER JM, DOUGADOS M, EMERY P et al.: Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: 12-month results of a phase IIB, double- blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 2263-71.
6. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38: 727-35.
7. PREVOO ML, VAN 'T HOF MA, KUPER HH, VAN LEEUWEN MA, Van de PUTTE LB, Van RIEL PL: Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
8. WARE JE Jr, SHERBOURNE CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.